SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following a significant Q4 earnings and revenue beat, driven by accelerating Miplyffa sales that have ignited community optimism around the company's commercial transformation and potential European expansion. However, active discussions also highlight persistent concerns over management's long-term vision, historical stock performance, and the financial implications of a recent adverse legal ruling.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY saw a significant intraday rally driven by President Trump's declarations that the war in Iran is "pretty much complete," though community sentiment is split between those seizing on the rebound and skeptics warning of a "scam pump" amidst ongoing geopolitical and oil market uncertainty.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Anticipation is surging for SELLAS Life Sciences' pivotal Phase 3 REGAL trial results for its AML immunotherapy, GPS, with community discussion highlighting strong confidence in potential "curative outcomes" as evidence suggests patients are living longer than expected, fueling speculation of a massive short squeeze.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is surging following impressive 12-month Phase 2 data for its bladder cancer treatment, NDV-01, showing a durable 76% complete response rate and securing $160 million in financing for Phase 3. The community is buzzing with excitement over the clinical progress and funding, actively debating whether the significant momentum and volume can drive sustained gains.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

Casey's General Stores is trending due to recent strong earnings results that outperformed expectations, coupled with an optimistic fiscal year outlook and ongoing strategic expansion plans. The community is actively discussing the company's resilient "pizza and gas" business model and its valuation as it continues to grow within the convenience store sector.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as the National Oceanic and Atmospheric Administration deemed its consolidated deep-seabed mining application in substantial compliance, a critical regulatory step forward. The community views this as a major de-risking event, underscoring the strategic need for critical minerals for national security and the EV/AI revolution, with many anticipating significant future milestones.

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

AN2 Therapeutics Inc

AN2 Therapeutics is trending due to a recently closed $40 million private placement and a research collaboration with GSK, igniting a fervent short-squeeze narrative among traders and leading to speculative price targets while others warn of a sharp reversal given the private placement's lower valuation.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF is trending amidst heightened global tensions from the Middle East conflict pushing oil prices higher and recent weak jobs data. Community discussions are sharply split, with some anticipating a significant market downturn while others foresee a "short squeeze" and a broader recovery driven by hopes of de-escalation and economic support.

Constellation Software, Inc. is a holding company, which acquires, manages and builds vertical market software businesses. It operates through the following segments: Public and Private Sector. The Public Sector segment focuses on government and government related customers. The Private Sector segment includes business units focused on commercial customers. The company was founded by Mark Henri Leonard and James D. Foy on August 23, 1995 and is headquartered in Toronto, Canada.

Constellation Software Inc

Constellation Software is a key topic of discussion following strong financial results, including robust revenue and cash flow growth, alongside a new strategic governance agreement with Sabre Corp. The community is actively dismissing recent market weakness as an overreaction to broader software sector concerns, asserting the company's established acquisition model and deep value proposition.

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals (XENE) is experiencing a significant surge following exceptionally strong Phase 3 X-TOLE2 trial results for its epilepsy treatment, azetukalner, which surpassed expectations and positions the drug as a differentiated Kv7 potassium channel opener. The market is buzzing with excitement over the robust efficacy, even as some investors react to a subsequent common shares offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compared to Estimates, Casey's (CASY) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Casey's (CASY) give a sense of how its business performed in the quarter ended January 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Casey's General Stores (CASY) Beats Q3 Earnings Estimates

Casey's (CASY) delivered earnings and revenue surprises of +16.05% and -2.65%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?

Casey`s General Stores Inc. Q3 Income Advances

(RTTNews) - Casey`s General Stores Inc. (CASY) announced a profit for its third quarter that Increased, from the same period last year...

Casey's Announces Third Quarter Results

Caseys General Stores, Inc. ('Casey's' or the 'Company') (Nasdaq: CASY) one of the leading convenience store chains in the United States, today announced financial results for the three and nine...

Casey's Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Casey's General Stores (NASDAQ: CASY) will release Q3 earnings on March 9. Analysts expect EPS of $2.97 and revenue of $4.04 billion. Shares fell 0.9% on Friday. Check analyst ratings and price...

Fieldview Capital Management LLC Purchases 3,367 Shares of Casey's General Stores, Inc. $CASY

Fieldview Capital Management LLC boosted its position in shares of Casey's General Stores, Inc. (NASDAQ:CASY - Free Report) by 92.0% in the third quarter, according to the company in its most recent...

Barclays PLC Has $89.95 Million Position in Casey's General Stores, Inc. $CASY

Barclays PLC raised its position in Casey's General Stores, Inc. (NASDAQ:CASY - Free Report) by 717.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and...

Korn Ferry, Hewlett Packard Enterprise And 3 Stocks To Watch Heading Into Monday

U.S. stock futures up, Korn Ferry, ZIM, Lantheus, HPE, and Caseys General Stores in focus for earnings. Check out premarket coverage.read more...

Dimensional Fund Advisors LP Has $252.83 Million Stock Holdings in Casey's General Stores, Inc. $CASY

Dimensional Fund Advisors LP increased its position in Casey's General Stores, Inc. (NASDAQ:CASY - Free Report) by 2.0% during the third quarter, according to the company in its most recent 13F...

Ulta Beauty Q4 Earnings on Deck: Should Investors Expect a Beat?

ULTA gears up for Q4 results with loyalty-fueled sales momentum, digital gains and brand launches, but margin pressure and rising costs may have weighed on earnings.


This account has been verified as an official CASY representative.

Verified Account

tester

eventtracking testing the char

$CASY Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $3.51 up 49.36% YoY
• Reported revenue of $3.92B up 0.32% YoY
• Casey&#39;s expects fiscal 2026 EBITDA to increase 18% to 20%, with inside same-store sales growing 3.5% to 4.5%. Inside margin is projected at 41.5% to 42.5% for the fiscal year.

Stocktwits

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of $3.51 up 49.36% YoY
• Reported revenue of $3.92B up 0.32% YoY
• Casey's expects fiscal 2026 EBITDA to increase 18% to 20%, with inside same-store sales growing 3.5% to 4.5%. Inside margin is projected at 41.5% to 42.5% for the fiscal year.

This account has been verified as an official STOCKTWITS representative.

Stocktwits Earnings

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $CASY earnings today?

Stocktwits Polls

The latest report shows a strong EPS beat of $3.49 but a revenue miss, sparking debate over the underlying financial health.

Despite mixed Q4 results and a 'Cramered' call, many investors view the company as a 'rock solid' long-term investment, expecting continued upward trajectory.

CASY
Casey's General Stores, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CASY News

CASYCasey's General Stores, Inc.